



## Unaudited Financial Results for the Quarter Ended 30<sup>th</sup> June, 2010

Particulars	Quarter ended on		Year ended on	
	30/06/2010	30/06/2009	31/03/2010	31/03/2009
	Unaudited	Unaudited	Audited	Audited
<b>1. Income</b>				
<b>a) Gross Sales</b>	<b>140.15</b>	<b>112.71</b>	<b>559.00</b>	<b>429.67</b>
Less : Excise Duty	(12.67)	(8.27)	(45.12)	(35.31)
Net Sales/Income from Operations	127.48	104.44	513.88	394.37
b) Other Operating Income	0.32	0.14	4.87	2.57
<b>1. Total Income</b>	<b>127.80</b>	<b>104.58</b>	<b>518.75</b>	<b>396.94</b>
<b>2. Expenditure</b>				
a) (Increase)/Decrease in stock in trade and work in progress	(16.19)	(10.45)	(52.06)	(79.94)
b) Consumption of Raw Materials	106.46	87.66	419.91	372.44
c) Employees Cost	3.46	2.44	13.90	10.83
d) Depreciation & Amortisations	4.35	2.67	10.07	6.97
e) Other Expenditure	8.33	8.01	44.67	28.40
<b>2. Total Expenditure</b>	<b>106.41</b>	<b>90.33</b>	<b>436.49</b>	<b>338.70</b>
<b>3. Profit from Operations before Other Income, Interest &amp; Exceptional Items</b>	<b>21.39</b>	<b>14.25</b>	<b>82.26</b>	<b>58.23</b>
4. Other Income				
5. Profit before Interest & Exceptional Items(3 + 4)	21.39	14.25	82.26	58.23
6. Interest	7.89	5.47	38.22	28.34
7. Profit after interest but before Exceptional Items (5-6)	13.50	8.78	44.04	29.90
8. Exceptional Items	-	-	-	-
<b>9. Profit (+)/Loss(-) from Ordinary Activities before tax (7 + 8)</b>	<b>13.50</b>	<b>8.78</b>	<b>44.04</b>	<b>29.90</b>
10. Tax expenses	2.97	1.05	9.84	5.97
<b>11. Net Profit(+)/ Loss(-) from Ordinary Activities after tax (9 - 10)</b>	<b>10.53</b>	<b>7.73</b>	<b>34.20</b>	<b>23.93</b>
12. Extra Ordinary Items	-	-	-	-

<b>13. Net Profit (+)/ Loss(-) for the period (11-12)</b>	<b>10.53</b>	<b>7.73</b>	<b>34.20</b>	<b>23.93</b>
14. Paid-up equity share capital (Face Value Rs. 10/- each)	61.89	10.75	37.25	10.75
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	121.37	89.30
<b>16. Earnings Per Share (EPS)</b>				
- Basic EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.77	7.19	17.91	22.68
- Diluted EPS before extraordinary items for the period for the year to date and for the previous year (not to be annualised)	2.77	7.19	17.91	22.68
- Basic EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.77	7.19	17.91	22.68
- Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	2.77	7.19	17.91	22.68
17. Public Shareholding :				
-Number of Shares	38,346,994	2,997,060	13,706,029	2,998,960
-Percentage of Shareholding	61.96	27.88	36.79	27.90
18. Promoters and Promoter Group Shareholding (non-encumbered) :				
- Number of shares	23,545,020	7,752,440	23,545,020	7,750,540
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
- Percentage of shares (as a % of the total share capital of the company)	38.04	72.12	63.21	72.10

#### Notes:

- 1) The above results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 20th July, 2010.
- 2) These results for the quarter ended 30th June, 2010 are subject to a "Limited Review" by the Statutory Auditors of the Company.
- 3) There were no investor complaints pending at the beginning of the quarter and there is no investor complaint pending at the end of the quarter.
- 4) During the Quarter, the company
  - a) Got EU- GMP Accreditation for its Cephalosporin manufacturing facility at Derabassi, granting approval or sales in EU of three molecules manufactured by the Company
  - b) Got "COS" (Certificate of Suitability) for Cefuroxime Axetil Amorphous, for sale in European Union from European Directorate for Quality of Medicines and Healthcare
  - c) Executed successfully 5 Custom Synthesis orders for innovator companies based in US and Europe

- 5) The Equity Shares of the Company have been listed at the Bombay Stock Exchange Limited (Designated) and the National Stock Exchange of with effect from 1st July, 2010.
- 6) The above financials results are on standalone basis.
- 7) There is not more than one reportable segment; hence, information as per AS-17 is not required to be disclosed.
- 8) Figures of the previous year have been rearranged / regrouped wherever necessary.

**For Parabolic Drugs Ltd.**

**Place : Chandigarh**  
**Date:20<sup>th</sup> July, 2010**

Sd/-  
**Pranav Gupta**  
**Managing Director**